Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Keros Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- +15 vs. Q3 2022
- Shares held
- 19.7M
- +1.69M (+9.4%) vs. Q3 2022
- Total value
- $948.2M
- +$269.1M (+39.6%) vs. Q3 2022
- New holders
- 29
- 44 more added
- Sold out
- 14
- 31 more reduced
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KROS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 132 | $198.6M |
| Q1 2026 | 151 | $205.6M |
| Q4 2025 | 166 | $408.4M |
| Q3 2025 | 155 | $558.0M |
| Q2 2025 | 139 | $479.6M |
| Q1 2025 | 156 | $428.6M |
| Q4 2024 | 161 | $582.1M |
| Q3 2024 | 164 | $2.03B |
| Q2 2024 | 152 | $1.44B |
| Q1 2024 | 147 | $2.08B |
| Q4 2023 | 121 | $1.02B |
| Q3 2023 | 107 | $730.6M |
| Q2 2023 | 123 | $901.0M |
| Q1 2023 | 129 | $937.0M |
| Q4 2022 | 126 | $948.2M |
| Q3 2022 | 113 | $680.1M |
| Q2 2022 | 104 | $479.7M |
| Q1 2022 | 106 | $893.0M |
| Q4 2021 | 99 | $944.5M |
| Q3 2021 | 89 | $545.4M |
| Q2 2021 | 80 | $599.7M |
| Q1 2021 | 83 | $887.0M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Keros Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 142,961 | $6.86M | 0.00% | +81,440+132.4% | Added |
| Goldman Sachs Group Inc | 145,822 | $7.00M | 0.00% | −30,542−17.3% | Reduced |
| Sphera Funds Management Ltd. | 158,757 | $7.62M | 2.40% | −48,062−23.2% | Reduced |
| Northern Trust Corp | 174,764 | $8.39M | 0.00% | +11,817+7.3% | Added |
| Millennium Management LLC | 181,277 | $8.71M | 0.01% | +181,277 | New |
| Woodline Partners LP | 196,699 | $9.45M | 0.13% | −145,794−42.6% | Reduced |
| CHI Advisors LLC | 215,059 | $10.3M | 2.75% | +14,830+7.4% | Added |
| Soleus Capital Management, L.P. | 233,116 | $11.2M | 1.61% | +87,116+59.7% | Added |
| Opaleye Management Inc. | 238,000 | $11.4M | 3.97% | −83,300−25.9% | Reduced |
| Clal Insurance Enterprises Holdings Ltd | 299,000 | $14.4M | 0.22% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 349,748 | $16.8M | 0.00% | +33,599+10.6% | Added |
| Citadel Advisors LLC | 405,471 | $19.5M | 0.02% | −22,636−5.3% | Reduced |
| Citigroup Inc | 412,103 | $19.8M | 0.03% | −64,020−13.4% | Reduced |
| Darwin Global Management, Ltd. | 428,532 | $20.6M | 12.81% | +428,532 | New |
| Franklin Resources Inc | 472,751 | $22.7M | 0.01% | −247−0.1% | Reduced |
| Point72 Asset Management, L.P. | 520,536 | $25.0M | 0.09% | +428,696+466.8% | Added |
| First Light Asset Management, LLC | 592,412 | $28.4M | 2.64% | −5,801−1.0% | Reduced |
| Price T Rowe Associates Inc | 621,189 | $29.8M | 0.00% | +611,459+6,284.3% | Added |
| Candriam Luxembourg S.C.A. | 625,914 | $30.1M | 0.20% | +264,125+73.0% | Added |
| Nantahala Capital Management, LLC | 792,093 | $38.0M | 3.44% | −53,599−6.3% | Reduced |
| State Street Corp | 968,138 | $46.5M | 0.00% | +34,626+3.7% | Added |
| Vanguard Group Inc | 1,045,320 | $50.2M | 0.00% | +138,746+15.3% | Added |
| Alkeon Capital Management LLC | 1,392,402 | $66.9M | 0.50% | +183,580+15.2% | Added |
| BlackRock Inc. | 1,638,326 | $78.7M | 0.00% | +177,136+12.1% | Added |
| OrbiMed Advisors LLC | 1,679,417 | $80.6M | 1.54% | 00.0% | Unchanged |
| FMR LLC | 3,679,089 | $176.7M | 0.02% | −184,437−4.8% | Reduced |
| Fairmount Funds Management LLC | 0 | $0 | 0.00% | −272,498−100.0% | Sold out |
| Deep Track Capital, LP | 0 | $0 | 0.00% | −248,500−100.0% | Sold out |
| Altium Capital Management LP | 0 | $0 | 0.00% | −88,000−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −33,321−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −22,427−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −19,919−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −12,829−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −9,620−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −8,344−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −2,380−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −1,372−100.0% | Sold out |
| Almanack Investment Partners, LLC. | 0 | $0 | 0.00% | −884−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Jefferies Group LLC | – | – | – | – | Not filed |
| Wipfli Financial Advisors LLC, | – | – | – | – | Not filed |